Skip navigation

Now Available: Fetal RhD NIPT

Plan ahead for your Rh negative pregnant patients

Panorama™ NIPT orders received beginning April 1, 2024 are eligible to receive fetal RhD status

Get highly accurate fetal RhD NIPT

Natera’s Fetal RhD NIPT is backed by the largest fetal RhD NIPT clinical validation study with confirmed outcomes in the US.1


Rh- patients

Sensitivity: 100%, 95% CI* (98.9-100%)

Fetal Rh+

n = 356/356

Specificity: 99.3%, 95% CI (97.6-99.8%)

Fetal Rh-

n = 295/297

In the validation study, fetal RhD status was reported for 99.7% of patients (n=653/655)

*CI=confidence interval. In clinical use false negatives and false positives are possible and may occur.

Upcoming Webinar

Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk

Thursday, June 6th, 2024 | 9:30-10:15 AM PT / 12:30-1:15 PM ET | 30 min webinar, 15 min live QA

Join our presentation for a:

  • Review of historical methods for, and importance of, determining Rh factor status during pregnancy
  • Introduction of new data from the largest clinical validation study for fetal RhD to date in the US, with 650+ Rh negative pregnant people and confirmation by serology on all newborns
  • Discussion of how fetal RhD NIPT adds to current management of pregnant people who are Rh negative

Presented by Jeffrey T. Meltzer, MD, MBA, Senior Medical Director and Vivienne Souter MD, MPH, Medical Director.

Inform decisions about RhD immune globulin

“…the use of NIPT to prioritize use of RhIg and conserve RhIg supply is a reasonable consideration in the practice setting that is experiencing RhIg shortages. Noninvasive fetal red blood cell antigen genotyping utilizing cell-free DNA (cfDNA) isolated from maternal plasma has demonstrated high sensitivity and specificity for detection of fetal Rh(D) antigen status”

ACOG Rho(D) Immune Globulin Shortages Practice Advisory, updated April 20242

Order with ease

Provide comprehensive prenatal screening with the #1 ordered NIPT and carrier screen5

  • Order Fetal RhD NIPT on the same form with the Panorama™ Horizon™ Combo Kit
  • No additional sample required
  • Receive results on the Panorama™ report

Robust support for you and your patients

  • Clear, actionable reports
  • Broad in-network coverage and financial access programs for patients who qualify. Learn more
  • Complimentary pre- and post-test genetic information sessions with Natera’s board-certified genetic counselors
  • NEVA, Natera’s Educational Virtual Assistant, which provides 24-7 access to results in English and Spanish. Learn more.

Incorporate Fetal RhD NIPT for your pregnant patients

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Meltzer et al., Validation of a SNP-based Prenatal cell-free DNA screening for Fetal RhD Status in a Large US Cohort, ACOG Annual Clinical and Scientific Meeting, May 2024, San Francisco, CA.

2ACOG Rho(D) Immune Globulin Shortages Practice Advisory. March 2024, updated April 2024

Fetal RhD NIPT provides a genotyping test result that determines the RhD gene sequence associated with fetal RhD status for pregnant RHD- (negative) people. Fetal RhD genotype does not always correlate with the phenotype. Panorama™ and Fetal RhD NIPT have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). CAP accredited, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.

icon-angle icon-bars icon-times